Neogenomics Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences

NeoGenomics (NEO) CEO, Mark Mallon on Q4 2021 Results - Earnings Call Transcript

NeoGenomics (NASDAQ: NEO ) reported its Q4 earnings results on Wednesday, February 23, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings NeoGenomics reported in-line EPS of $-0.14 versus an estimate of $-0.14. Revenue was Full story available on Benzinga.com

NeoGenomics press release (NEO): Q4 Non-GAAP EPS of -$0.14 beats by $0.01.Revenue of $125.73M (-0.2% Y/Y) in-line.Shares +0.27% PM.Consolidated gross profit for the fourth quarter

NeoGenomics (NEO) delivered earnings and revenue surprises of -7.69% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

On relatively calm days, the tokens that jump often have exciting stories to tell.

NeoGenomics (NEO) unit Inivata reported positive data for its RaDaR liquid biopsy test in head and neck squamous cell carcinoma ((HNSCC)).In the LIONESS study, blood samples taken from

FT. MYERS, FL / ACCESSWIRE / February 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today anno

Neogenomics Inc. (NEO) shares closed 1.3% lower than its previous 52 week low, giving the company a market cap of $2B. The stock is currently down 37.3% year-to-date, down 61.0% over the past 12 months, and up 155.1% over the past five years. This week, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 4.1%. Trading Activity Trading volume this week was 3.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 400.4% The company's stock price performance over the past 12 months lags the peer average by -800.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 345.2% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

See two of the featured stocks from this month's model portfolios.

Neogenomics Inc. (NEO) shares closed today at 0.6% above its 52 week low of $24.85, giving the company a market cap of $3B. The stock is currently down 26.8% year-to-date, down 52.7% over the past 12 months, and up 190.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 28.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 453.2% The company's stock price performance over the past 12 months lags the peer average by -373.2% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 391.9% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.